Previous Article | Next Article 
Journal of Virology, January 1999, p. 398-403, Vol. 73, No. 1
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Analysis of Murine CD8+ T-Cell Clones
Specific for the Dengue Virus NS3 Protein: Flavivirus
Cross-Reactivity and Influence of Infecting Serotype
Anne C.
Spaulding,
Ichiro
Kurane,
Francis A.
Ennis, and
Alan L.
Rothman*
Center for Infectious Diseases and Vaccine
Research, University of Massachusetts Medical Center, Worcester,
Massachusetts 01655
Received 21 July 1998/Accepted 5 October 1998
 |
ABSTRACT |
Serotype-cross-reactive dengue virus-specific cytotoxic T
lymphocytes (CTL) induced during a primary dengue virus infection are
thought to play a role in the immunopathogenesis of dengue hemorrhagic
fever (DHF) during a secondary dengue virus infection. Although there
is no animal model of DHF, we previously reported that murine dengue
virus-specific CTL responses are qualitatively similar to human dengue
virus-specific CTL responses. We used BALB/c mice to study the
specificity of the CTL response to an immunodominant epitope on the
dengue virus NS3 protein. We mapped the minimal
H-2Kd-restricted CTL epitope to residues 298 to
306 of the dengue type 2 virus NS3 protein. In short-term T-cell lines
and clones, the predominant CD8+ CTL to this epitope in
mice immunized with dengue type 2 virus or vaccinia virus expressing
the dengue type 4 virus NS3 protein were cross-reactive with dengue
type 2 or type 4 virus, while broadly serotype-cross-reactive CTL were
a minority population. In dengue type 3 virus-immunized mice, the
predominant CTL response to this epitope was broadly serotype
cross-reactive. All of the dengue virus-specific CTL clones studied
also recognized the homologous NS3 sequences of one or more closely
related flaviviruses, such as Kunjin virus. The critical contact
residues for the CTL clones with different specificities were mapped
with peptides having single amino acid substitutions. These data
demonstrate that primary dengue virus infection induces a complex
population of flavivirus-cross-reactive NS3-specific CTL clones in mice
and suggest that CTL responses are influenced by the viral serotype.
These findings suggest an additional mechanism by which the order of
sequential flavivirus infections may influence disease manifestations.
 |
INTRODUCTION |
The family Flaviviridae
consists of over 65 arthropod-transmitted viruses that are known to
infect humans. The dengue viruses, of which there are four serotypes,
are the flaviviruses of greatest global health importance, causing an
estimated 100 million infections each year (10, 28). Dengue
hemorrhagic fever (DHF), the severe clinical form of dengue virus
infection, has been shown to occur more frequently in individuals who
have experienced a previous infection with a different dengue virus
serotype (1, 37, 40), suggesting an immunopathologic basis
for severe dengue illness.
Members of our laboratory have been studying memory dengue
virus-specific cytotoxic T-lymphocyte (CTL) responses in order to
understand the potential protective and immunopathologic effects of
these CTLs during secondary dengue virus infections. CD4+
and CD8+ CTL responses induced by primary dengue virus
infection have been characterized with bulk cultures and at the clonal
level in a small number of adult human volunteers who were infected under experimental conditions with live tissue culture-passaged dengue
viruses (8, 17, 18, 23, 27). Both serotype-specific and
serotype-cross-reactive CTLs have been isolated from most subjects.
Most serotype-cross-reactive CTLs have been directed at epitopes on
nonstructural proteins, particularly the NS1-NS2A and NS3 proteins.
Several different patterns of cross-reactivity have been observed; some
CTL clones have recognized several but not all dengue virus serotypes,
other clones have recognized all four dengue virus serotypes, and other
clones have also recognized closely related flaviviruses, such as West
Nile virus (WNV) (14). The frequencies of different CTL
specificities have varied among the subjects studied; however, it has
not been possible to relate these differences to host factors, such as
HLA type, or differences in the viruses causing primary infections.
We previously reported that T-lymphocyte responses to primary dengue
virus infection in mice are qualitatively similar to human T-lymphocyte
responses to dengue virus in bulk cultures and at the clonal level
(34-36). Both serotype-specific and serotype-cross-reactive dengue virus-specific CTL clones were isolated from BALB/c mice, and
the serotype-cross-reactive clones recognized epitopes on the NS1-NS2A
and NS3 proteins. One CD8+ CTL epitope, recognized in the
context of H-2Kd, was mapped to amino acids 296 to 310 of the dengue type 2 virus NS3 protein (34). This
epitope is completely conserved in dengue type 4 virus.
To define further the potential importance of these memory dengue
virus-specific CD8+ CTLs in secondary dengue virus
infection, we analyzed in more detail the specificity of the
NS3-specific CTL clones. As reported here, we noted that all four
serotypes of dengue viruses as well as closely related flaviviruses
showed a high degree of amino acid homology at the epitope mentioned
above. Specific single amino acid differences in this epitope had
different effects on recognition by different CTL clones, accounting
for both dengue virus subcomplex-specific and dengue virus
complex-cross-reactive patterns of responses. We also explored the
effects of the infecting virus on the patterns of CTL responses generated.
 |
MATERIALS AND METHODS |
Cells.
Target cell lines were the P815 murine mastocytoma
line (H-2d), L929 (H-2k)
cell lines transfected with Ld (T1.1.1) or
Dd (T4.8.3) and provided by Carol Reiss of New
York University (26), and an L929 cell line transfected with
Kd(L-Kd-172) and obtained from Jack
Bennick of the National Institutes of Health (5). The
control L929 cell line (DAP) was a gift from Carol Reiss.
Viruses.
Mouse-adapted dengue type 2 virus (strain New
Guinea C), type 3 virus (strain PR6), and type 4 virus (strain 814669)
were kindly provided by Jack McCown of the Walter Reed Army Institute of Research. Tissue culture-adapted dengue type 2 virus (strain New
Guinea C) was graciously donated by Walter Brandt, also of the Walter
Reed Army Institute of Research, and was propagated in C6/36 cells.
Recombinant vaccinia viruses expressing the dengue type 2 or type 3 virus NS3 protein were provided by Margo Brinton of Georgia State
University (41), and a recombinant vaccinia virus expressing
the dengue type 4 virus NS3 protein was provided by Ching-Juh Lai of
the National Institutes of Health (6, 35).
Peptides.
Synthetic peptides were prepared by
9-fluorenylmethoxycarbonyl chemistry with a Symphony automated peptide
synthesizer (Rainin Instruments, Woburn, Mass.) at the Peptide Core
Facility at the University of Massachusetts Medical Center.
Mouse immunization and preparation of spleen cells.
Immunization of mice and preparation of clones from spleen cells were
performed as previously described (34-36). Briefly, male BALB/c (H-2d) mice (Charles River Breeding
Laboratories, Wilmington, Mass.) were immunized at 4 to 8 weeks of age
with dengue virus (0.2 to 0.3 ml containing approximately 1 × 106 PFU) or with one to three doses of recombinant vaccinia
virus expressing the dengue virus NS3 protein (0.1 ml containing
approximately 2 × 107 PFU). Splenocytes were
collected 4 to 8 weeks after immunization and incubated in RPMI 1640 medium with 5 × 105 M 2-mercaptoethanol, 10% fetal
calf serum (Hyclone Laboratories, Logan, Utah), and 0.5 ml of dengue
virus or 1 µM peptide. Approximately every 2 weeks, the cells were
stimulated with either 2 × 106 gamma-irradiated
dengue type 2 virus-infected P815 cells or 3 × 107
gamma-irradiated syngeneic nonimmune spleen cells plus 1 µM dengue virus NS3 peptide. Cells were fed twice weekly with medium containing 10% rat lectin-free T-cell growth factor as a source of interleukin 2.
Cytotoxicity assays.
Cytotoxicity assays were performed as
previously described (34, 35). Briefly, P815 cells were
radioactively labeled by incubation with
Na251CrO4 for 1 h, washed
extensively, and seeded at 0.5 × 104 cells per well
in 96-well U-bottom plates. Serial dilutions of peptides were added
directly to the target cells in the wells. The clones were then added
at various effector/target cell ratios. The plates were incubated at
37°C for 4 h. The supernatant fluid was collected with a
Supernatant Collecting System (Skatron, Inc., Sterling, Va.). A gamma
counter detected the release of 51Cr. Minimum
51Cr release was measured by sampling supernatant fluid
from labeled target cells incubated in medium alone. Maximum
51Cr release was determined from wells in which labeled
target cells were incubated with Renex. Assays were performed in
triplicate, and the mean of the samples was used to calculate percent
specific lysis with the following formula: percent specific lysis = 100 × [(experimental 51Cr release
minimum
51Cr release)/(maximum 51Cr release
minimum 51Cr release)]. Minimum 51Cr release
did not exceed 30% of maximum 51Cr release. Lysis of
peptide-coated target cells was considered significant when it was
8% more than lysis of target cells in the absence of peptides and
values were found significantly different by the Student t test.
 |
RESULTS |
Identification of the minimal epitope recognized by NS3-specific
CTL clones.
We previously mapped a dominant epitope on the dengue
type 4 virus NS3 protein recognized by
H-2Kd-restricted CD8+ CTL clones
derived from dengue type 2 virus-immunized BALB/c mice to a
15-amino-acid region between residues 296 and 310, ARGYISTRVEMGEAA (34). To define further the specific epitope recognized by
these CTL clones, we tested for the recognition of target cells
incubated with truncations of this 15-mer. Data obtained with clone
2D65 are shown in Table 1; similar data
were obtained with clone 2D42 (data not shown). Initial data suggested
that the minimal sequence was the 9-mer representing residues 298 (G)
to 306 (M). Analysis of recognition of this 9-mer peptide and
truncations thereof showed that the C-terminal methionine was required
for recognition by these CTL clones. The 8-mer peptide representing
residues 299 to 306 could be recognized by these clones, but
recognition of this peptide was reproducibly less efficient than
recognition of the 9-mer peptide representing residues 298 to 306.
View this table:
[in this window]
[in a new window]
|
TABLE 1.
Recognition of truncations of the dengue type 4 virus NS3
peptide (residues 296 to 310) by CD8+ CTL
clone 2D65a
|
|
CTL clones derived from dengue type 2 virus-immunized mice
recognize the corresponding sequence of dengue type 4 but not dengue
type 1 or dengue type 3 virus.
We previously reported that the
sequence of the 15-mer recognized by the CTL clones was completely
conserved between dengue type 2 and dengue type 4 viruses
(34). We next examined the published sequences to determine
the corresponding sequences of other dengue virus serotypes and related
flaviviruses (Table 2) (2, 3, 7, 13,
22, 25, 30, 33, 39). This analysis showed that this region of the
NS3 protein is highly conserved among flaviviruses. Compared to the
dengue type 2 or type 4 virus sequence, there was only a single amino
acid difference at peptide position 8 in dengue type 1 and dengue type
3 viruses, a single amino acid difference at position 9 in Kunjin
virus, and two amino acid differences in Murray Valley encephalitis
virus. WNV and Japanese encephalitis virus had three amino acid
differences, and the less closely related yellow fever virus had seven
amino acid differences.
Since serotype cross-reactivity is most clinically relevant among the
dengue viruses, we first tested for recognition of the
dengue type 1 or
type 3 virus sequence by the CTL clones (Fig.
1). Identical results were obtained with
recombinant vaccinia
viruses expressing the full-length NS3 proteins of
dengue type
2, dengue type 3, and dengue type 4 viruses or synthetic
peptides
representing the dengue type 2 or type 4 virus or the dengue
type
1 or type 3 virus sequences; none of six clones isolated from
dengue type 2 virus-immunized mice recognized the dengue type
3 virus
NS3 sequence.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 1.
Dengue virus serotype specificity of CD8+
CTL clones isolated from dengue type 2 virus-immunized mice. Clones
2D42 (hatched bars) and 2D65 (open bars) were isolated from dengue type
2 virus-immunized BALB/c mice and tested at an effector/target cell
ratio of 4:1. P815 target cells were uninfected ( ); infected with
dengue type 2 virus (D2V), wild-type vaccinia virus (vvCont), or
recombinant vaccinia viruses (vv) expressing the full-length dengue
type 2, dengue type 3, or dengue type 4 virus NS3 proteins (vvD2NS3,
vvD3NS3, and vvD4NS3, respectively); or pulsed with the dengue type 4 virus (residues 296 to 310) or dengue type 3 virus (residues 297 to
311) peptides (D4-NS3 peptide and D3-NS3 peptide, respectively) at 10 µM.
|
|
Dengue type 4 virus NS3-immunized mice do have
serotype-cross-reactive CTL responses.
We next tested whether the
dengue type 1 or type 3 virus NS3 sequences could be recognized by
H-2Kd-restricted CTLs. Splenocytes from mice
immunized with a recombinant vaccinia virus expressing the dengue type
4 virus NS3 protein were stimulated in bulk cultures with the dengue
type 4 virus NS3 peptide (296 to 310) and tested for recognition of the
dengue type 2 or type 4 virus and dengue type 1 or type 3 virus NS3
peptides (Table 3). At day 40 of
culturing, the predominant response was specific for the dengue type 4 virus NS3 sequence, but there was significant, if less efficient,
recognition of the dengue type 3 virus NS3 peptide. This result
suggested that serotype-cross-reactive CTLs were present but at a lower
level than CTLs specific for the dengue type 2 or type 4 virus peptide.
The bulk cultures were then split and restimulated with either the
dengue type 4 or the dengue type 3 virus NS3 peptide. The CTL lines
were then tested for recognition of both peptides. The CTL line
restimulated with the dengue type 4 virus NS3 peptide maintained
recognition of the dengue type 4 virus NS3 peptide but showed little if
any recognition of the dengue type 3 virus NS3 peptide at day 54 of
culturing. In contrast, the CTL line restimulated with the dengue type
3 virus NS3 peptide showed a high level of cross-reactivity for both
peptides. Both CTL lines recognized the target epitope in an
H-2Kd-restricted manner (data not shown). These
results suggest that serotype-cross-reactive CTLs were initially
present at a low level but that they could be selectively expanded by
stimulation with the dengue type 3 virus NS3 peptide.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Recognition of dengue virus NS3 peptides by short-term
CTL lines from dengue type 4 virus
NS3-immunized micea
|
|
We then used this stimulation protocol to isolate dengue virus
serotype-cross-reactive CD8
+ CTL clones. Splenocytes from
mice immunized with dengue type
4 virus were stimulated with the dengue
type 3 virus NS3 peptide
and cloned by limiting dilution. Five CTL
clones were isolated;
all recognized both the dengue type 4 and the
dengue type 3 virus
NS3 peptides in the context of
H-2
Kd (data not
shown).
Dengue virus NS3-specific CTL from dengue type 3 virus-immunized
mice are serotype cross-reactive.
We wanted to characterize
further the serotype cross-reactivity of dengue virus NS3-specific CTL
lines. We immunized mice with dengue type 3 virus to determine the
pattern of CTL serotype cross-reactivity induced by the dengue type 3 virus NS3 epitope. Splenocytes from dengue type 3 virus-immunized mice
were stimulated in vitro with the dengue type 3 virus NS3 peptide and
tested for the recognition of the dengue type 1 or type 3 virus and
dengue type 2 or type 4 virus NS3 peptides (Table
4). These CTLs lysed target cells pulsed
with either peptide, indicating that the predominant CTL response in
dengue type 3 virus-immunized mice is broadly dengue virus serotype
cross-reactive. These CTLs also lysed target cells infected with
recombinant vaccinia viruses expressing either the dengue type 2, dengue type 3, or dengue type 4 virus NS3 protein or target cells
infected with dengue type 2 virus, indicating that these CTLs recognize
the naturally processed epitope (Table 4). We isolated 14 CTL clones
from this CTL line by limiting dilution; all the clones isolated
recognized both the dengue type 3 and the dengue type 4 virus NS3
peptides in the context of H-2Kd (data not
shown).
Flavivirus specificity of dengue virus NS3-specific CTL
clones.
We next studied the specificity of the CTL clones for
other closely related flaviviruses. Representative data obtained with CTL clones each corresponding to the different specificities are shown
in Fig. 2. Clone 2D42, which was
generated from dengue type 2 virus-immunized mice after stimulation
with dengue type 2 virus-infected P815 cells, did not recognize the
dengue type 1 or type 3 virus peptide but did recognize the homologous
peptides of Kunjin virus and Murray Valley encephalitis virus. Clone
E10.6, which was generated from a dengue type 4 virus-immunized mouse
after stimulation with the dengue type 3 virus NS3 peptide, recognized
the NS3 peptides from all dengue virus serotypes and Kunjin virus. This
clone could recognize the Murray Valley encephalitis virus sequence but
less efficiently than clone 2D42. Clone 0.5-1, which was generated from
dengue type 3 virus-immunized mice after stimulation with the dengue
type 3 virus NS3 peptide, was similarly dengue virus serotype
cross-reactive and able to recognize the Kunjin virus peptide but did
not show any recognition of the Murray Valley encephalitis virus
peptide. None of the three clones recognized the homologous peptides of
Japanese encephalitis virus, WNV, or yellow fever virus.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 2.
Flavivirus specificity of CD8+ CTL clones.
Clones 2D42, E10.6, and 0.5-1 were tested in separate experiments.
Virus sequences are designated as follows: D4, dengue type 4 (identical
to dengue type 2); D3, dengue type 3 (identical to dengue type 1); KUN,
Kunjin; MVE, Murray Valley encephalitis; JEV, Japanese encephalitis
(identical to WNV); and YFV, yellow fever. Data are expressed as a
percentage of the D4 response, calculated as 100 × [(percent
specific lysis of target cells incubated with indicated
peptide)/(percent specific lysis of target cells incubated with the
dengue type 4 virus peptide)]. For clone 2D42, the effector/target
cell ratio was 1:1, and percentages of specific lysis were as follows:
no peptide, 3%; 5,000 nM, 36%; 500 nM, 35%; 50 nM, 36%; and 5 nM,
30%. For clone E10.6, the effector/target cell ratio was 2:1, and
percentages of specific lysis were as follows: no peptide, 5%; 5,000 nM, 58%; 500 nM, 59%; 50 nM, 65%; and 5 nM, 55%. For clone 0.5-1, the effector/target cell ratio was 2:1, and percentages of specific
lysis were as follows: no peptide, 3%; 5,000 nM, 29%; 500 nM, 30%;
50 nM, 28%; and 5 nM, 27%.
|
|
Identification of the critical contact residues for dengue
virus-specific CTL clones.
The different patterns of recognition
of related flaviviruses suggested that the clones differed in the
critical contact residues of the NS3 peptide. To characterize this idea
further, we tested the three above-mentioned clones for the recognition
of peptides with individual substitutions at each of the nine residues
of the dengue type 4 virus NS3 sequence. To facilitate the comparison of the recognition of these peptides and the peptides of the related flaviviruses, we based the substitutions on the corresponding amino
acids of other flaviviruses, except for position 1, where we
substituted alanine for the conserved glycine. Recognition of these
peptides by clones 2D42, E10.6, and 0.5-1 is shown in Fig.
3.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 3.
Effects of single amino acid substitutions on
recognition by dengue virus-specific CTL clones. Clones 2D42, E10.6,
and 0.5-1 were tested in separate experiments. Data are expressed as a
percentage of the response to dengue type 4 virus, calculated as
described in the legend to Fig. 2. The peptide designation specifies
the amino acid and position number in the dengue type 4 virus NS3
sequence followed by the substituted amino acid. Peptides E305G and
M306L are the dengue type 3 virus and Kunjin virus peptides,
respectively.
|
|
The second and ninth residues are most important for binding to
H-2
Kd (
32). Substitution of
tryptophan for tyrosine at the second
residue, as in yellow fever
virus, abolished recognition by clones
E10.6 and 0.5-1 and drastically
inhibited recognition by clone
2D42. Substitution of leucine for
methionine at the ninth position,
as in Kunjin virus, did not impair
recognition by any of the clones,
in keeping with the known suitability
of leucine at this position
for binding to
Kd
(
32). Substitution of histidine for threonine at the fifth
residue, as in yellow fever virus, impaired recognition by all
clones.
Peptide recognition by clone 2D42 was also inhibited by
substitutions
at positions 6, 7, and 8, which included the single
substitution in the
dengue type 1 or type 3 virus peptide. In
comparison, peptide
recognition by clones E10.6 and 0.5-1 was
inhibited most by
substitutions at positions 3 and
4.
 |
DISCUSSION |
This study expands on our previous work showing that
H-2Kd-restricted CD8+ CTL clones
isolated from dengue type 2 virus-immunized BALB/c mice recognize a
dengue type 2 and type 4 virus-cross-reactive epitope between amino
acids 296 and 310 of the NS3 protein (34). We defined the
minimal epitope as amino acids 298 to 306 of the dengue type 2 virus
NS3 protein. We also generated additional CD8+ CTL clones
that recognized the same epitope from mice immunized with dengue type 3 or dengue type 4 virus. We found that these CTL clones were either
dengue virus subcomplex (dengue type 2 or type 4 virus) specific or
broadly serotype cross-reactive. In addition, all of these CTL clones
recognized the corresponding sequences of one or more other flaviviruses.
The NS3 protein appears to be a dominant target for dengue
virus-specific CD4+ and CD8+ T cells, and most
dengue virus NS3-specific T cells are serotype cross-reactive (14,
27, 35). Multiple human CD4+ T-cell epitopes on the
NS3 protein have been identified (15, 19, 21, 29, 41).
Although few human CD8+ T-cell epitopes have been mapped on
the NS3 protein, bulk-culture CD8+ CTL recognition of the
NS3 protein was detected in six of eight dengue virus-immunized
subjects in one study (27). CTLs from several mouse strains
have been found to recognize the NS3 protein of dengue virus as well as
other flaviviruses, including WNV, Murray Valley encephalitis virus,
and Kunjin virus (11, 24, 31, 35). The abundance of T-cell
epitopes on the flavivirus NS3 protein is not well explained. The
relative conservation of the NS3 protein among flaviviruses suggests
that the requirements for the enzymatic functions of this protein may
restrict the ability of flaviviruses to survive mutations. The minimal
peptide recognized by the H-2Kd-restricted CTLs
that we studied, GYISTRVEM, contains the typical Kd binding motif, with tyrosine at position 2 and a hydrophobic amino acid at position 9 (32). This
Kd binding motif is conserved in Kunjin virus,
Murray Valley encephalitis virus, WNV, and Japanese encephalitis virus,
suggesting that this epitope may be recognized by CTLs induced in mice
by infection with these flaviviruses.
Memory dengue virus serotype cross-reactive CTLs may play a protective
role in limiting viral replication, but they have also been proposed to
contribute to the increased risk for DHF during secondary dengue virus
infections (20). Levels of soluble CD8 in serum were found
to be elevated in children with DHF compared to those with dengue
fever, supporting an immunopathologic role for CD8+ CTLs
(7a, 16). The NS3-specific CTL clones that we studied recognized one or more heterologous dengue virus serotypes and theoretically could be activated during a secondary dengue virus infection.
These results also demonstrate CTL cross-reactivity with other
flaviviruses, specifically Kunjin and Murray Valley encephalitis viruses, which have the most homology with dengue viruses at the epitope in question. Similarly, Kurane et al. reported that some human
dengue virus-specific CD4+ CTL clones could recognize WNV
or yellow fever virus (14). Interestingly, not all
flavivirus-cross-reactive CTL clones isolated from dengue
virus-immunized humans and mice were able to recognize all four dengue
virus serotypes (41). We used peptides incorporating single
substitutions into the background of the dengue type 2 or type 4 virus
NS3 peptide sequence to explain this unexpected pattern of specificity.
Peptide recognition by clone 2D42, which recognized the dengue type 2 or type 4, Kunjin, and Murray Valley encephalitis virus sequences, was
sensitive to the substitution at position 8 in the dengue type 1 or
type 3 virus sequence, whereas substitutions at positions 4 and 9, as
in Murray Valley encephalitis virus, had little effect. In contrast,
clone 0.5-1, which was broadly dengue virus serotype cross-reactive but
unable to recognize the Murray Valley encephalitis virus sequence, was
unaffected by the substitution at position 8 but was unable to
recognize the peptide incorporating the position 4 substitution.
CTL cross-reactivity with other flaviviruses suggests that protective
and immunopathologic effects might occur during sequential infections
with flaviviruses other than dengue virus. In a large field study of a
Japanese encephalitis virus vaccine, Hoke et al. observed that the
incidence of DHF was somewhat lower in immunized children than in
control subjects over a 2-year period, although the difference was not
statistically significant (12). Several studies have also
found that the antibody response to candidate live dengue virus
vaccines was enhanced in subjects previously immunized with a yellow
fever virus vaccine (4, 38). Epidemiologic studies have not
fully addressed this possibility, in part because the geographic
distribution of dengue virus has historically overlapped that of only
Japanese encephalitis virus. More recently, however, dengue virus
infections have become more frequent in areas of the Western Hemisphere
where yellow fever is endemic and in Australia where Kunjin and Murray
Valley encephalitis viruses circulate (9). These
epidemiologic changes increase the opportunities for sequential
flavivirus infections.
We found that the patterns of dengue virus serotype cross-reactivity in
short-term T-cell lines and clones differed in mice immunized with
different dengue virus serotypes. In BALB/c mice immunized with dengue
type 2 virus or a recombinant vaccinia virus expressing the dengue type
4 virus NS3 protein, the predominant CTL responses were dengue type 2 or type 4 virus cross-reactive, with a low level of CTL recognition of
the dengue type 1 or type 3 virus sequence. In mice immunized with
dengue type 3 virus, the CTL responses to this epitope were broadly
serotype cross-reactive. Substantial variability in the levels of
serotype-cross-reactive T-cell responses have been noted in studies of
dengue virus-immunized humans, but an effect of the viral serotype on
these responses has not been apparent. In studies of murine CTL
responses to WNV and Kunjin virus, Hill et al. also noted nonreciprocal
CTL flavivirus cross-reactivity (11). Although a detailed
analysis of the levels of CTLs with different specificities, such as by
use of intracellular gamma interferon staining in response to peptide
stimulation, would be necessary to provide a definitive demonstration
of this effect, our data suggest that there is nonreciprocal CTL
cross-reactivity among the dengue virus serotypes as well.
Epidemiologic studies have suggested that the order of acquisition of
dengue virus infections is important; specifically, having a sequence
of infections in which dengue type 2 virus is the agent of secondary
dengue virus infection increases the odds of DHF or dengue shock
syndrome (37, 40). Differences in virulence between the
different dengue virus serotypes have been proposed to explain this
finding. Our results raise another possible explanation, that CTLs
induced by other serotypes may recognize dengue type 2 virus to a
greater extent than the reverse.
The full story on the importance of T-cell immunity in DHF pathogenesis
is not yet known, but clarifying the specificity and cross-reactivity
of T-cell clones could give insights into how cell-mediated immunity
might work in nature. Although dengue virus-infected mice do not
manifest DHF, our results suggest that the immune response to
sequential dengue virus infection in mice may provide information
useful for directing further human studies.
 |
ACKNOWLEDGMENTS |
We thank Jurand Janus, Kim West, Anita Leporati, and Lichen Dai
for technical assistance.
This work was supported by grants K11 AI00971 and T32 AI07272 from the NIAID.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Center for
Infectious Diseases and Vaccine Research, University of Massachusetts
Medical Center, 55 Lake Ave. North, Worcester, MA 01655. Phone: (508) 856-4182. Fax: (508) 856-4890. E-mail:
alan.rothman{at}ummed.edu.
Present address: Department of Virology I, National Institute of
Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan.
 |
REFERENCES |
| 1.
|
Burke, D. S.,
A. Nisalak,
D. E. Johnson, and R. M. Scott.
1988.
A prospective study of dengue infections in Bangkok.
Am. J. Trop. Med. Hyg.
38:172-180.
|
| 2.
|
Castle, E.,
U. Leidner,
T. Nowak, and G. Wengler.
1986.
Primary structure of the West Nile flavivirus genome region coding for all nonstructural proteins.
Virology
149:10-26[Medline].
|
| 3.
|
Coia, G.,
M. D. Parker,
G. Speight,
M. E. Byrne, and E. G. Westaway.
1988.
Nucleotide and complete amino acid sequences of Kunjin virus: definitive gene order and characteristics of the virus-specified proteins.
J. Gen. Virol.
69:1-21[Abstract/Free Full Text].
|
| 4.
|
Eckels, K. H.,
S. C. Kliks,
D. R. Dubois,
L. M. Wahl, and W. H. Bancroft.
1985.
The association of enhancing antibodies with seroconversion in humans receiving a dengue-2 live-virus vaccine.
J. Immunol.
135:4201-4203[Abstract].
|
| 5.
|
Eisenlohr, L. C.,
J. W. Yewdell, and J. R. Bennink.
1992.
A transient transfection system for identifying biosynthesized proteins processed and presented to class I MHC restricted T lymphocytes.
J. Immunol. Methods
154:131-138[Medline].
|
| 6.
|
Falgout, B.,
M. Pethel,
Y. M. Zhang, and C. J. Lai.
1991.
Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins.
J. Virol.
65:2467-2475[Abstract/Free Full Text].
|
| 7.
|
Fu, J.,
B. H. Tan,
E. H. Yap,
Y. C. Chan, and Y. H. Tan.
1992.
Full-length cDNA sequence of dengue type 1 virus (Singapore strain S275/90).
Virology
188:953-958[Medline].
|
| 7a.
| Green, S. Personal communication.
|
| 8.
|
Green, S.,
I. Kurane,
R. Edelman,
C. O. Tacket,
K. H. Eckels,
D. W. Vaughn,
C. H. Hoke, Jr., and F. A. Ennis.
1993.
Dengue virus-specific human CD4+ T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination.
J. Virol.
67:5962-5967[Abstract/Free Full Text].
|
| 9.
|
Gubler, D. J., and G. G. Clark.
1995.
Dengue/dengue hemorrhagic fever: the emergence of a global health problem.
Emerg. Infect. Dis.
1:55[Medline].
|
| 10.
|
Halstead, S. B.
1992.
The XXth century dengue pandemic: need for surveillance and research.
World Health Stat. Q.
45:292-298[Medline].
|
| 11.
|
Hill, A. B.,
A. Mullbacher,
C. Parrish,
G. Coia,
E. G. Westaway, and R. V. Blanden.
1992.
Broad cross-reactivity with marked fine specificity in the cytotoxic T cell response to flaviviruses.
J. Gen. Virol.
73:1115-1123[Abstract/Free Full Text].
|
| 12.
|
Hoke, C. H.,
A. Nisalak,
N. Sangawhipa,
S. Jatanasen,
T. Laorakapongse,
B. L. Innis,
S. Kotchasenee,
J. B. Gingrich,
J. Latendresse,
K. Fukai, and D. S. Burke.
1988.
Protection against Japanese encephalitis by inactivated vaccines.
N. Engl. J. Med.
319:608-614[Abstract].
|
| 13.
|
Irie, K.,
P. M. Mohan,
Y. Sasaguri,
R. Putnak, and R. Padmanabhan.
1989.
Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain).
Gene
75:197-211[Medline].
|
| 14.
|
Kurane, I.,
M. A. Brinton,
A. L. Samson, and F. A. Ennis.
1991.
Dengue virus-specific, human CD4+ CD8 cytotoxic T-cell clones: multiple patterns of virus cross-reactivity recognized by NS3-specific T-cell clones.
J. Virol.
65:1823-1828[Abstract/Free Full Text].
|
| 15.
|
Kurane, I.,
L. C. Dai,
P. G. Livingston,
E. Reed, and F. A. Ennis.
1993.
Definition of an HLA-DPw2-restricted epitope on NS3, recognized by a dengue virus serotype-cross-reactive human CD4+ CD8 cytotoxic T-cell clone.
J. Virol.
67:6285-6288[Abstract/Free Full Text].
|
| 16.
|
Kurane, I.,
B. L. Innis,
S. Nimmannitya,
A. Nisalak,
A. Meager,
J. Janus, and F. A. Ennis.
1991.
Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue.
J. Clin. Investig.
88:1473-1480.
|
| 17.
|
Kurane, I.,
B. L. Innis,
A. Nisalak,
C. Hoke,
S. Nimmannitya,
A. Meager, and F. A. Ennis.
1989.
Human T cell responses to dengue virus antigens. Proliferative responses and interferon gamma production.
J. Clin. Investig.
83:506-513.
|
| 18.
|
Kurane, I.,
A. Meager, and F. A. Ennis.
1989.
Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity.
J. Exp. Med.
170:763-775[Abstract/Free Full Text].
|
| 19.
|
Kurane, I.,
Y. Okamoto,
L. C. Dai,
L. L. Zeng,
M. A. Brinton, and F. A. Ennis.
1995.
Flavivirus-cross-reactive, HLA-DR15-restricted epitope on NS3 recognized by human CD4+ CD8 cytotoxic T lymphocyte clones.
J. Gen. Virol.
76:2243-2249[Abstract/Free Full Text].
|
| 20.
|
Kurane, I.,
A. L. Rothman,
P. G. Livingston,
S. Green,
S. J. Gagnon,
J. Janus,
B. L. Innis,
S. Nimmannitya,
A. Nisalak, and F. A. Ennis.
1994.
Immunopathologic mechanisms of dengue hemorrhagic fever and dengue shock syndrome.
Arch. Virol.
9:59-64.
|
| 21.
|
Kurane, I.,
L. Zeng,
M. A. Brinton, and F. A. Ennis.
1998.
Definition of an epitope on NS3 recognized by human CD4+ cytotoxic T lymphocyte clones cross-reactive for dengue virus types 2, 3, and 4.
Virology
240:169-174[Medline].
|
| 22.
|
Lee, E.,
C. Fernon,
R. Simpson,
R. C. Weir,
C. M. Rice, and L. Dalgarno.
1990.
Sequence of the 3' half of the Murray Valley encephalitis virus genome and mapping of the nonstructural proteins NS1, NS3, and NS5.
Virus Genes
4:197-213[Medline].
|
| 23.
|
Livingston, P. G.,
I. Kurane,
L. C. Dai,
Y. Okamoto,
C. J. Lai,
R. Men,
S. Karaki,
M. Takiguchi, and F. A. Ennis.
1995.
Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities.
J. Immunol.
154:1287-1295[Abstract].
|
| 24.
|
Lobigs, M.,
C. E. Arthur,
A. Mullbacher, and R. V. Blanden.
1997.
The flavivirus nonstructural protein NS3 is a dominant source of cytotoxic T cell peptide determinants.
Virology
202:195-201.
|
| 25.
|
Mackow, E.,
Y. Makino,
B. T. Zhao,
Y. M. Zhang,
L. Markoff,
A. Buckler-White,
M. Guiler,
R. Chanock, and C. J. Lai.
1987.
The nucleotide sequence of dengue type 4 virus: analysis of genes coding for nonstructural proteins.
Virology
159:217-228[Medline].
|
| 26.
|
Margulies, D. H.,
G. A. Evans,
K. Ozato,
R. D. Camerini-Otero,
K. Tanaka,
E. Appella, and J. G. Seidman.
1983.
Expression of H-2Dd and H-2Ld mouse major histocompatibility antigen genes in L cells after DNA-mediated gene transfer.
J. Immunol.
130:463-470[Abstract].
|
| 27.
|
Mathew, A.,
I. Kurane,
A. L. Rothman,
L. L. Zeng,
M. A. Brinton, and F. A. Ennis.
1996.
Dominant recognition by human CD8+ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a.
J. Clin. Investig.
98:1684-1694[Medline].
|
| 28.
|
Monath, T. P.
1994.
Dengue: the risk to developed and developing countries.
Proc. Natl. Acad. Sci. USA
91:2395-2400[Abstract/Free Full Text].
|
| 29.
|
Okamoto, Y.,
I. Kurane,
A. M. Leporati, and F. A. Ennis.
1998.
Definition of the region on NS3 which contains multiple epitopes recognized by dengue virus serotype-cross-reactive and flavivirus-cross-reactive, HLA-DPw2-restricted CD4+ T cell clones.
J. Gen. Virol.
79:697-704[Abstract].
|
| 30.
|
Osatomi, K., and H. Sumiyoshi.
1990.
Complete nucleotide sequence of dengue type 3 virus genome RNA.
Virology
176:643-647[Medline].
|
| 31.
|
Parrish, C. R.,
G. Coia,
A. Hill,
A. Mullbacher,
E. G. Westaway, and R. V. Blanden.
1991.
Preliminary analysis of murine cytotoxic T cell responses to the proteins of the flavivirus Kunjin using vaccinia virus expression.
J. Gen. Virol.
72:1645-1653[Abstract/Free Full Text].
|
| 32.
|
Rammensee, H. G.,
T. Friede, and S. Stevanovic.
1995.
MHC ligands and peptide motifs: first listing.
Immunogenetics
41:178-228[Medline].
|
| 33.
|
Rice, C. M.,
E. M. Lenches,
S. R. Eddy,
S. J. Shin,
R. L. Sheets, and J. H. Strauss.
1985.
Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution.
Science
229:726-733[Abstract/Free Full Text].
|
| 34.
|
Rothman, A. L.,
I. Kurane, and F. A. Ennis.
1996.
Multiple specificities in the murine CD4+ and CD8+ T-cell response to dengue virus.
J. Virol.
70:6540-6546[Abstract/Free Full Text].
|
| 35.
|
Rothman, A. L.,
I. Kurane,
C. J. Lai,
M. Bray,
B. Falgout,
R. Men, and F. A. Ennis.
1993.
Dengue virus protein recognition by virus-specific murine CD8+ cytotoxic T lymphocytes.
J. Virol.
67:801-806[Abstract/Free Full Text].
|
| 36.
|
Rothman, A. L.,
I. Kurane,
Y. M. Zhang,
C. J. Lai, and F. A. Ennis.
1989.
Dengue virus-specific murine T-lymphocyte proliferation: serotype specificity and response to recombinant viral proteins.
J. Virol.
63:2486-2491[Abstract/Free Full Text].
|
| 37.
|
Sangkawibha, N.,
S. Rojanasuphot,
S. Ahandrik,
S. Viriyapongse,
S. Jatanasen,
V. Salitul,
B. Phanthumachinda, and S. B. Halstead.
1984.
Risk factors for dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak.
Am. J. Epidemiol.
120:653-669[Abstract/Free Full Text].
|
| 38.
|
Scott, R. M.,
K. H. Eckels,
W. H. Bancroft,
P. L. Summers,
J. M. McCown,
J. H. Anderson, and P. K. Russell.
1983.
Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status.
J. Infect. Dis.
148:1055-1060[Medline].
|
| 39.
|
Sumiyoshi, H.,
C. Mori,
I. Fuke,
K. Morita,
S. Kuhara,
J. Kondou,
Y. Kikuchi,
H. Nagamatu, and A. Igarashi.
1987.
Complete nucleotide sequence of the Japanese encephalitis virus genome RNA.
Virology
161:497-510[Medline].
|
| 40.
|
Thein, S.,
M. M. Aung,
T. N. Shwe,
M. Aye,
A. Zaw,
K. Aye,
K. M. Aye, and J. Aaskov.
1997.
Risk factors in dengue shock syndrome.
Am. J. Trop. Med. Hyg.
56:566-572.
|
| 41.
|
Zeng, L.,
I. Kurane,
Y. Okamoto,
F. A. Ennis, and M. A. Brinton.
1996.
Identification of amino acids involved in recognition by dengue virus NS3-specific, HLA-DR15-restricted cytotoxic CD4+ T-cell clones.
J. Virol.
70:3108-3117[Abstract].
|
Journal of Virology, January 1999, p. 398-403, Vol. 73, No. 1
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Yauch, L. E., Zellweger, R. M., Kotturi, M. F., Qutubuddin, A., Sidney, J., Peters, B., Prestwood, T. R., Sette, A., Shresta, S.
(2009). A Protective Role for Dengue Virus-Specific CD8+ T Cells. J. Immunol.
182: 4865-4873
[Abstract]
[Full Text]
-
Noisakran, S., Perng, G. C.
(2008). Alternate Hypothesis on the Pathogenesis of Dengue Hemorrhagic Fever (DHF)/Dengue Shock Syndrome (DSS) in Dengue Virus Infection. Exp. Biol. Med.
233: 401-408
[Abstract]
[Full Text]
-
Selin, L. K., Brehm, M. A.
(2007). Frontiers in Nephrology: Heterologous Immunity, T Cell Cross-Reactivity, and Alloreactivity. J. Am. Soc. Nephrol.
18: 2268-2277
[Abstract]
[Full Text]
-
Wang, T., Gao, Y., Scully, E., Davis, C. T., Anderson, J. F., Welte, T., Ledizet, M., Koski, R., Madri, J. A., Barrett, A., Yin, Z., Craft, J., Fikrig, E.
(2006). {gamma}{delta} T Cells Facilitate Adaptive Immunity against West Nile Virus Infection in Mice. J. Immunol.
177: 1825-1832
[Abstract]
[Full Text]
-
Mitaksov, V., Fremont, D. H.
(2006). Structural Definition of the H-2Kd Peptide-binding Motif. J. Biol. Chem.
281: 10618-10625
[Abstract]
[Full Text]
-
Calvert, A. E., Huang, C. Y.-H., Kinney, R. M., Roehrig, J. T.
(2006). Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge. J. Gen. Virol.
87: 339-346
[Abstract]
[Full Text]
-
Doisne, J.-M., Urrutia, A., Lacabaratz-Porret, C., Goujard, C., Meyer, L., Chaix, M.-L., Sinet, M., Venet, A.
(2004). CD8+ T Cells Specific for EBV, Cytomegalovirus, and Influenza Virus Are Activated during Primary HIV Infection. J. Immunol.
173: 2410-2418
[Abstract]
[Full Text]
-
Shresta, S., Kyle, J. L., Snider, H. M., Basavapatna, M., Beatty, P. R., Harris, E.
(2004). Interferon-Dependent Immunity Is Essential for Resistance to Primary Dengue Virus Infection in Mice, Whereas T- and B-Cell-Dependent Immunity Are Less Critical. J. Virol.
78: 2701-2710
[Abstract]
[Full Text]
-
Harvey, T. J., Anraku, I., Linedale, R., Harrich, D., Mackenzie, J., Suhrbier, A., Khromykh, A. A.
(2003). Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine Development. J. Virol.
77: 7796-7803
[Abstract]
[Full Text]
-
Twiddy, S. S., Woelk, C. H., Holmes, E. C.
(2002). Phylogenetic evidence for adaptive evolution of dengue viruses in nature. J. Gen. Virol.
83: 1679-1689
[Abstract]
[Full Text]
-
Zivna, I., Green, S., Vaughn, D. W., Kalayanarooj, S., Stephens, H. A. F., Chandanayingyong, D., Nisalak, A., Ennis, F. A., Rothman, A. L.
(2002). T Cell Responses to an HLA-B*07-Restricted Epitope on the Dengue NS3 Protein Correlate with Disease Severity. J. Immunol.
168: 5959-5965
[Abstract]
[Full Text]
-
Regner, M., Lobigs, M., Blanden, R. V., Milburn, P., Mullbacher, A.
(2001). Antiviral Cytotoxic T Cells Cross-Reactively Recognize Disparate Peptide Determinants from Related Viruses but Ignore More Similar Self- and Foreign Determinants. J. Immunol.
166: 3820-3828
[Abstract]
[Full Text]
-
Huang, C. Y.-H., Butrapet, S., Pierro, D. J., Chang, G.-J. J., Hunt, A. R., Bhamarapravati, N., Gubler, D. J., Kinney, R. M.
(2000). Chimeric Dengue Type 2 (Vaccine Strain PDK-53)/Dengue Type 1 Virus as a Potential Candidate Dengue Type 1 Virus Vaccine. J. Virol.
74: 3020-3028
[Abstract]
[Full Text]